In vitro screening for chemokine antagonists

Bibliography

• Metchnikoff E. Lectures on the comparative pathology of inflammation. Keegan paul, trench, trubner and co., paternoster house, charing cross road. 1893. p. 218
   Google Scholar
• Deuel TF, Keim PS, Farmer M, Heinrikson RL. Amino acid sequence of human platelet factor 4. Proc Natl Acad Sci USA 1977;74:2256-8
   PubMed Web of Science ®Google Scholar
• Walz A, Peveri P, Aschauer H, Baggiolini M. Purification and amino acid sequencing of NAF, a novel neutrophil-activating factor produced by monocytes. Biochem Biophys Res Commun 1987;149:755-61
   PubMed Web of Science ®Google Scholar
• Yoshimura T, Matsushima K, Tanaka S, et al. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci USA 1987;84:9233-7
   PubMed Web of Science ®Google Scholar
• Baggiolini M. Chemokines and leukocyte traffic. Nature 1998;392:565-8
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121-7
   PubMed Web of Science ®Google Scholar
• Fredriksson R, Schioth HB. The repertoire of g-protein-coupled receptors in fully sequenced genomes. Mol Pharmacol 2005;67:1414-25
   PubMed Web of Science ®Google Scholar
• Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000;52:145-76
   PubMed Web of Science ®Google Scholar
• Horuk R, Chitnis CE, Darbonne WC, et al. A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor. Science 1993;261:1182-4
   PubMed Web of Science ®Google Scholar
• van Berkel V, Barrett J, Tiffany HL, et al. Identification of a gammaherpesvirus selective chemokine binding protein that inhibits chemokine action. J Virol 2000;74:6741-7
   PubMed Web of Science ®Google Scholar
• Loetscher P, Seitz M, Baggiolini M, Moser B. Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J Exp Med 1996;184:569-77
   PubMed Web of Science ®Google Scholar
• Struyf S, Proost P, Schols D, et al. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J Immunol 1999;162:4903-9
   PubMed Web of Science ®Google Scholar
• Petkovic V, Moghini C, Paoletti S, et al. Eotaxin-3/CCL26 is a natural antagonist for CC chemokine receptors 1 and 5. A human chemokine with a regulatory role. J Biol Chem 2004;279:23357-63
   PubMed Web of Science ®Google Scholar
• Horuk R. Chemokine receptors. Growth Factor Rev 2001;12:313-35
   PubMed Web of Science ®Google Scholar
• Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49:4721-32
   PubMed Web of Science ®Google Scholar
• De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 2008;77:1656-64
   Google Scholar
• FDA Approval for Plerixafor. Available from: http://www.cancer.gov/cancertopics/druginfo/fda-plerixafor
   Google Scholar
• Ribeiro S, Horuk R. The clinical potential of chemokine receptor antagonists. Pharmacol Ther 2005;107:44-58
   PubMed Web of Science ®Google Scholar
• Bennett GL, Horuk R. Iodination of chemokines for use in receptor binding analysis. Methods Enzymol 1997;288:134-48
   PubMed Web of Science ®Google Scholar
• Schioppa T, Uranchimeg B, Saccani A, et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 2003;198:1391-402
   PubMed Web of Science ®Google Scholar
• New DC, Wong YH. Characterization of CHO cells stably expressing a G alpha 16/z chimera for high throughput screening of GPCRs. Assay Drug Dev Technol 2004;2:269-80
   PubMed Web of Science ®Google Scholar
• Kohler RE, Comerford I, Townley S, et al. Antagonism of the chemokine receptors CXCR3 and CXCR4 reduces the pathology of experimental autoimmune encephalomyelitis. Brain Pathol 2008;18:504-16
   PubMed Web of Science ®Google Scholar
• Cashen A, Lopez S, Gao F, et al. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant 2008;14:1253-61
   PubMed Web of Science ®Google Scholar
• Hesselgesser J, Liang M, Hoxie J, et al. Identification and characterization of the CXCR4 chemokine receptor in human T cell lines: ligand binding, biological activity, and HIV-1 infectivity. J Immunol 1998;160:877-83
   PubMed Web of Science ®Google Scholar
• Schols D, Struyf S, Van Damme J, et al. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997;186:1383-8
   PubMed Web of Science ®Google Scholar
• Gupta SK, Pillarisetti K, Thomas RA, Aiyar N. Pharmacological evidence for complex and multiple site interaction of CXCR4 with SDF-1alpha: implications for development of selective CXCR4 antagonists. Immunol Lett 2001;78:29-34
   PubMed Web of Science ®Google Scholar
• Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008;112:990-8
   PubMed Web of Science ®Google Scholar
• Fransen S, Bridger G, Whitcomb JM, et al. Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition. Antimicrob Agents Chemother 2008;52:2608-15
   PubMed Web of Science ®Google Scholar
• Crump MP, Gong JH, Loetscher P, et al. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. Embo J 1997;16:6996-7007
   PubMed Web of Science ®Google Scholar
• Edwards BS, Oprea T, Prossnitz ER, Sklar LA. Flow cytometry for high-throughput, high-content screening. Curr Opin Chem Biol 2004;8:392-8
   PubMed Web of Science ®Google Scholar
• Trinquet E, Fink M, Bazin H, et al. D-myo-inositol 1-phosphate as a surrogate of D-myo-inositol 1,4,5-tris phosphate to monitor G protein-coupled receptor activation. Anal Biochem 2006;358:126-35
   PubMed Web of Science ®Google Scholar
• Bradley J, Gill J, Bertelli F, et al. Development and automation of a 384-well cell fusion assay to identify inhibitors of CCR5/CD4-mediated HIV virus entry. J Biomol Screen 2004;9:516-24
   PubMed Web of Science ®Google Scholar
• Armour D, de Groot MJ, Edwards M, et al. The discovery of CCR5 receptor antagonists for the treatment of HIV infection: hit-to-lead studies. ChemMedChem 2006;1:706-9
   PubMed Web of Science ®Google Scholar
• Czaplewski LG, McKeating J, Craven CJ, et al. Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES. Characterization of active disaggregated chemokine variants. J Biol Chem 1999;274:16077-84
   PubMed Web of Science ®Google Scholar
• Neote K, DiGregorio D, Mak JY, et al. Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor. Cell 1993;72:415-25
   PubMed Web of Science ®Google Scholar
• Van Riper G, Nicholson DW, Scheid MP, et al. Induction, characterization, and functional coupling of the high affinity chemokine receptor for RANTES and macrophage inflammatory protein-1 alpha upon differentiation of an eosinophilic HL-60 cell line. J Immunol 1994;152:4055-61
   PubMed Web of Science ®Google Scholar
• Taub DD, Proost P, Murphy WJ, et al. Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J Clin Invest 1995;95:1370-6
   PubMed Web of Science ®Google Scholar
• Kenakin T, Jenkinson S, Watson C. Determining the potency and molecular mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther 2006;319:710-23
   PubMed Web of Science ®Google Scholar
• Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-77
   PubMed Web of Science ®Google Scholar
• Ditzel HJ, Rosenkilde MM, Garred P, et al. Schwartz TW. The CCR5 receptor acts as an alloantigen in CCR5Delta32 homozygous individuals: identification of chemokineand HIV-1-blocking human antibodies. Proc Natl Acad Sci USA 1998;95:5241-5
   PubMed Web of Science ®Google Scholar
• Fischereder M, Luckow B, Hocher B, et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001;357:1758-61
   PubMed Web of Science ®Google Scholar
• Napier C, Sale H, Mosley M, et al. Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem Pharmacol 2005;71:163-72
   PubMed Web of Science ®Google Scholar
• De Clercq E, Yamamoto N, Pauwels R, et al. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother 1994;38:668-74
   PubMed Web of Science ®Google Scholar
• Aids IL. Plerixafor: AMD 3100, AMD3100, JM 3100, SDZ SID 791. Drugs R D 2007;7:113-9
   Google Scholar
• Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272:1955-8
   PubMed Web of Science ®Google Scholar
• Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-7
   PubMed Web of Science ®Google Scholar
• Schols D, Este JA, Henson G, et al. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res 1997;35:147-56
   PubMed Web of Science ®Google Scholar
• De Clercq E. Hamao umezawa memorial award lecture: “An Odyssey in the Viral Chemotherapy Field”. Int J Antimicrob Agents 2001;18:309-28
   PubMed Web of Science ®Google Scholar
• Hatse S, Princen K, Bridger G, et al. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 2002;527:255-62
   PubMed Web of Science ®Google Scholar
• Hendrix CW, Collier AC, Lederman MM, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 2004;37:1253-62
   PubMed Web of Science ®Google Scholar
• Gladue RP, Zwillich SH, Clucas AT, Brown MF. CCR1 antagonists for the treatment of autoimmune diseases. Curr Opin Investig Drugs 2004;5:499-504
   PubMedGoogle Scholar
• Brown MF, Bahnck KB, Blumberg LC, et al. Piperazinyl CCR1 antagonists–optimization of human liver microsome stability. Bioorg Med Chem Lett 2007;17:3109-12
   PubMed Web of Science ®Google Scholar
• Zipp F, Hartung HP, Hillert J, et al. Blockade of chemokine signaling in patients with multiple sclerosis. Neurology 2006;67:1880-3
   PubMed Web of Science ®Google Scholar
• Vann L. End of 2007 brings extra activity. Autoimmune Drug Focus 2007;37:1
   Google Scholar
• Beaulieu A, Hasler F, Martin Mola E, et al. The efficacy and safety of a CCR2 receptor antagonist in the treatment of rheumatoid arthritis (RA). Ann Rheum Dis 2006;65(Suppl II):175. Avilable from: http://www.abstracts2view.com/eular/search.php?search=do&intMaxHits=10&where[]=&andornot[]=&query=CCR12+antagonist.
   Google Scholar
• Braddock M. 11th annual Inflammatory and Immune Diseases Drug Discovery and Development Summit 12-13 March 2007, San Francisco, USA. Expert Opin Investig Drugs 2007;16:909-17
   PubMed Web of Science ®Google Scholar
• Braddock M. Advances in anti-inflammatory therapeutics: 20-21 November 2006, London, UK. Expert Opin Investig Drugs 2007;16:257-61
   PubMedGoogle Scholar
• Johnson M, Li AR, Liu J, et al. Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3. Bioorg Med Chem Lett 2007;17:3339-43
   PubMed Web of Science ®Google Scholar
• Liang M, Mallari C, Rosser M, et al. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem 2000;275:19000-8
   PubMed Web of Science ®Google Scholar
• Gladue RP, Tylaska LA, Brissette WH, et al. CP-481,715: a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases. J Biol Chem 2003;278:40473-80
   PubMed Web of Science ®Google Scholar
• Gladue RP, Cole SH, Roach ML, et al. The human specific CCR1 antagonist CP-481,715 inhibits cell infiltration and inflammatory responses in human CCR1 transgenic mice. J Immunol 2006;176:3141-8
   PubMed Web of Science ®Google Scholar
• Combadiere C, Potteaux S, Rodero M, et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 2008;117:1649-57
   PubMed Web of Science ®Google Scholar
• Saederup N, Chan L, Lira SA, Charo IF. Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice: evidence for independent chemokine functions in atherogenesis. Circulation 2008;117:1642-8
   PubMed Web of Science ®Google Scholar
• Walters I, Austin C, Austin R, et al. Evaluation of a series of bicyclic CXCR2 antagonists. Bioorg Med Chem Lett 2008;18:798-803
   PubMed Web of Science ®Google Scholar
• Maggio R, Scarselli M, Novi F, et al. Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. J Neurochem 2003;87:631-41
   PubMed Web of Science ®Google Scholar
• Hilairet S, Bouaboula M, Carriere D, et al. Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. J Biol Chem 2003;278:23731-7
   PubMed Web of Science ®Google Scholar
• McGraw DW, Mihlbachler KA, Schwarb MR, et al. Liggett SB. Airway smooth muscle prostaglandin-EP1 receptors directly modulate beta2-adrenergic receptors within a unique heterodimeric complex. J Clin Invest 2006;116:1400-9
   PubMed Web of Science ®Google Scholar
• Rodriguez-Frade JM, Vila-Coro AJ, de Ana AM, et al. The chemokine monocyte chemoattractant protein-1 induces functional responses through dimerization of its receptor CCR2. Proc Natl Acad Sci USA 1999;96:3628-33
   PubMed Web of Science ®Google Scholar
• El-Asmar L, Springael JY, Ballet S, et al. Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. Mol Pharmacol 2005;67:460-9
   PubMed Web of Science ®Google Scholar
• Vila-Coro AJ, Mellado M, Martin de Ana A, et al. HIV-1 infection through the CCR5 receptor is blocked by receptor dimerization. Proc Natl Acad Sci USA 2000;97:3388-93
   PubMed Web of Science ®Google Scholar
• Vila-Coro AJ, Rodriguez-Frade JM, Martin De Ana A, et al. The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J 1999;13:1699-710
   PubMed Web of Science ®Google Scholar
• Babcock GJ, Farzan M, Sodroski J. Ligand-independent dimerization of CXCR4, a principal HIV-1 coreceptor. J Biol Chem 2003;278:3378-85
   PubMed Web of Science ®Google Scholar
• Trettel F, Di Bartolomeo S, Lauro C, et al. Ligand-independent CXCR2 dimerization. J Biol Chem 2003;278:40980-8
   PubMed Web of Science ®Google Scholar
• Milligan G, Wilson S, Lopez-Gimenez JF. The specificity and molecular basis of alpha1-adrenoceptor and CXCR chemokine receptor dimerization. J Mol Neurosci 2005;26:161-8
   PubMed Web of Science ®Google Scholar
• Smith MW, Carrington M, Winkler C, et al. CCR2 chemokine receptor and AIDS progression. Nat Med 1997;3:1052-3
   PubMed Web of Science ®Google Scholar
• Mellado M, Rodriguez-Frade JM, Vila-Coro AJ, et al. Chemokine control of HIV-1 infection. Nature 1999;400:723-4
   PubMed Web of Science ®Google Scholar